Friday 6 November 2026
Export ILMN’s income statement to Excel — free account
Illumina, Inc.
ILMN Healthcare Diagnostics & Research
Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
- Revenue
- +4.15%
- EPS
- +49.0%
- Free cash flow
- +49.8%
- Total debt
- +80.0%
Quarter to September 2026, against a year earlier
209.82
16.72
−7.38%
Follow ILMN
Alert me
Illumina, Inc. (ILMN) revenue by segment, product and region
Where the money comes from and where it goes
| Consumables | 3,227 | 74.30% |
|---|---|---|
| Service | 634 | 14.60% |
| Instruments | 482 | 11.10% |
| Gross margin | 66.08% | |
| Operating margin | 18.58% | |
| Pre-tax margin | 25.01% |
Revenue by product or service $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Services and Other | — | — | — | — | — | — | — | — | — | 366 15.26% |
| Also reported: a second breakdown of the same revenue | ||||||||||
| Consumables | 3,227 74.30% | 3,155 72.16% | 3,083 68.45% | 3,225 70.35% | 3,217 71.08% | 2,304 71.13% | 2,392 67.51% | 2,177 65.32% | 1,771 64.35% | 1,543 64.35% |
| Service | 634 14.60% | 716 16.38% | 717 15.92% | 631 13.77% | 558 12.33% | 504 15.56% | 614 17.33% | 584 17.52% | 463 16.82% | 366 15.26% |
| Instruments | 482 11.10% | 501 11.46% | 704 15.63% | 728 15.88% | 751 16.59% | 431 13.31% | 537 15.16% | 572 17.16% | 518 18.82% | 469 19.56% |
| Other Products | — | — | — | — | — | — | — | — | — | 20 0.83% |
| Total product revenue | 3,709 | 3,656 | 3,787 | 3,953 | 3,968 | 2,735 | 2,929 | 2,749 | 2,289 | — |
| Revenue | 4,343 | 4,372 | 4,504 | 4,584 | 4,526 | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 |
Gross profit by product or service $m, and margin
Revenue by segment $m
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRAIL | 0 0.00% | 55 1.26% | 93 2.06% | 55 1.20% | 12 0.27% | 0 0.00% | 0 0.00% | — | — | — | — | — |
| Consolidated Variable Interest Entities | — | — | — | — | — | — | 1 0.03% | 10 0.30% | 6 0.22% | — | — | 0 0.00% |
| Also reported: a second breakdown of the same revenue | ||||||||||||
| Sequencing | 3,985 91.76% | 3,993 91.33% | 4,112 91.30% | 4,171 90.99% | 4,109 90.79% | 2,879 88.89% | 3,068 86.59% | — | — | — | — | — |
| Microarray | 358 8.24% | 379 8.67% | 392 8.70% | 413 9.01% | 417 9.21% | 360 11.11% | 475 13.41% | — | — | — | — | — |
| Eliminations | — | — | — | — | — | — | — | — | — | (30) (1.25%) | — | — |
| Core Illumina | 4,343 | — | — | — | — | 3,239 | 3,543 | — | — | — | — | — |
| Revenue | 4,343 | 4,372 | 4,504 | 4,584 | 4,526 | 3,239 | 3,543 | 3,333 | 2,752 | 2,398 | 2,220 | 1,861 |
Operating income by segment $m, and margin
Revenue by region $m
| Line | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|
| United States | 1,207 54.37% | 951 51.08% | 715 50.29% | 568 49.49% | 529 50.09% | 499 55.27% | 347 52.11% |
| Europe | 527 23.74% | 467 25.06% | 355 24.96% | 291 25.37% | 278 26.33% | — | — |
| Asia-Pacific | 380 17.12% | 343 18.41% | 276 19.45% | 232 20.24% | 197 18.66% | 143 15.89% | 96 14.47% |
| Other Countries | 106 4.77% | 101 5.45% | 75 5.30% | 56 4.89% | 52 4.91% | 37 4.07% | 26 3.89% |
| Segment, Geographical, Groups of Countries, Group One [Member] (Deprecated 2013-01-31) | — | — | — | — | — | 163 18.06% | 141 21.15% |
| United Kingdom | — | — | — | — | — | 61 6.70% | 56 8.38% |
| Revenue | 2,220 | 1,861 | 1,421 | 1,149 | 1,056 | 903 | 666 |
Operating figures as reported in each quarter’s results release or filing
| Figure | Quarter | Latest | A year before | Change |
|---|---|---|---|---|
| Remaining performance obligations | Q3 FY2026 | $933.0M | $747.0M | +24.90% |